We use cookies to customise content for your subscription and for analytics.
If you continue to browse Lexology, we will assume that you are happy to receive all our cookies. For further information please read our Cookie Policy.

Search results

Order by: most recent most popular relevance



Results: 1-10 of 72

Evolution of the Common General Knowledge: Humanized Antibody Claims Upheld at the Canadian Patent Appeal Board
  • Bereskin & Parr LLP
  • Canada
  • August 26 2016

Applicants prevailed in the recent Commissioner’s Decision Re Chugai Seiyaku and Kabushiki Kaisha (CD 1398, hereinafter “Kaisha”) 1 from the Patent


Canadian patent term extension is coming
  • Bereskin & Parr LLP
  • Canada, European Union
  • October 18 2013

Canada and Europe announced an agreement in principle on a Comprehensive Economic and Trade Agreement (“CETA”) that will potentially increase Canadian


Patenting Polymorphs of Crystals Internationally
  • Bereskin & Parr LLP
  • Canada, European Union, Japan, USA
  • June 27 2016

Polymorphs are patentable subject matter in Canada and the U.S. Our prior article discussed some best practices to differentiate a new polymorph from


Supreme Court dismisses appeal from the bench in Sanofi-Aventis v. Apotex, Inc.
  • Bereskin & Parr LLP
  • Canada
  • May 8 2015

On April 21st, 2015, the Supreme Court of Canada dismissed from the bench an appeal from the Federal Court of Appeal decision inApotex Inc. v


The Myriad decision: what is the impact?
  • Bereskin & Parr LLP
  • Canada
  • June 20 2013

As we reported in our previous article, the Supreme Court of the United States issued its long awaited decision in the Myriad case on June 13, 2013


Biosimilar Approvals in the US and Canada - the ‘Patent Dance’
  • Bereskin & Parr LLP
  • Canada, USA
  • December 30 2015

The US and Canada each provide an abbreviated pathway (or shortcut) for a biosimilar manufacturer to get a product approved. The shortcut allows for a


What to expect when you are expecting to launch a drug in Canada regulatory overview
  • Bereskin & Parr LLP
  • Canada
  • March 2 2015

This article provides a brief overview of key regulatory issues to be aware of when marketing a drug in Canada. Price Regulation and Reimbursement


Federal court overturns Commissioner of Patents: claims with fixed dosages and dosing schedules held not to be methods of medical treatment
  • Bereskin & Parr LLP
  • Canada
  • January 16 2015

In AbbVie Biotechnology Ltd v Canada (Attorney General) "AbbVie" the Federal Court allowed AbbVie's appeal of a decision by the Commissioner of


Looking into the Crystal Ball - Protecting Polymporphs to Lengthen the Drug Patent Life Cycle
  • Bereskin & Parr LLP
  • Canada, USA
  • June 7 2016

Innovative pharmaceutical companies are increasingly attempting to patent improved forms of their original drug compound. Crystalline forms of a drug


Developing a Patent Family Bigger than the Brady Bunch
  • Bereskin & Parr LLP
  • Canada
  • June 2 2016

New drugs require a huge amount of innovation, time, capital and risk to get to market. Nobody should begrudge a drug company for seeking strong